Thrombosis Canada has reviewed recent reports from the United Kingdom and Europe relating to the SARS-CoV-2 (COVID-19) vaccine made by AstraZeneca and the development of a very rare type of thrombosis (blood clots) that is associated with thrombocytopenia (low blood platelets).
It is the view of Thrombosis Canada that, based all available evidence, people who receive the AstraZeneca vaccine are not at increased risk of developing blood clots when compared with the general population.
